TCT-48 Bioresorbable Scaffold Versus Metallic Drug-Eluting Stent in Patients at High Risk of Restenosis (COMPARE-ABSORB trial): Very Late Device Thrombosis While on Extended DAPT

Robert-Jan Van Geuns,Chun-Chin Chang,Bernard Chevalier,Tommaso Gori,Emanuele Barbato,Giuseppe Tarantini,Stephan Achenbach,Dariusz Dudek,Javier Escaned,Mohamed Abdel-Wahab,Giovanni Esposito,Jan Tijssen,Marie-Claude Morice,Yoshinobu Onuma,Pieter Smits

Journal of the American College of Cardiology（2019）

引用 0|浏览60

暂无评分

摘要

The COMPARE-ABSORB trial has shown noninferiority between the bioresorbable vascular scaffold (BVS) and the metallic everolimus-eluting stents (EES) at 1 year in composite safety and effectiveness outcomes, although BVS carries a higher device thrombosis rate than EES. Several studies indicated an

查看译文

关键词

late device thrombosis,restenosis,drug-eluting,compare-absorb

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要